Do GLP-1 Medications Cause Bone Loss in Women (and How to Protect Your Bones)?

If you are on a GLP-1 medication and have seen headlines about bone loss, it is a fair question to ask, especially for women moving through perimenopause and menopause. Here is a calm, evidence-based look at what is actually known, and what remains uncertain.

The short answer

GLP-1 medications like semaglutide and tirzepatide do not appear to attack bone directly. The bigger driver of any bone change seems to be the weight loss itself. Losing a meaningful amount of weight, by almost any method, tends to lower bone mineral density. Reviews describe GLP-1 drugs as having a fairly neutral to minimal direct effect on bone, while rapid or large weight loss is the part that can pull bone density down. The research on this drug class specifically is still limited, and results on fracture risk have been mixed rather than alarming.

Why weight loss and bone loss travel together

Your skeleton is a load-bearing structure that adapts to the forces placed on it. When you carry less weight, the mechanical load on your bones drops, and bone can follow. Research has long shown that when people with obesity lose significant weight through calorie restriction or surgery, markers of bone turnover rise and bone mineral density falls. These changes tend to show up once people lose roughly 7 to 10 percent of their body weight, which is well within the range many people reach on GLP-1 therapy. In other words, the concern is less "this drug is bad for bones" and more "significant weight loss asks something of your bones."

Why women around menopause may be more vulnerable

This is where the women-specific angle matters. Estrogen helps protect bone, and as it declines in perimenopause and menopause, bone loss speeds up on its own. Layering rapid weight loss on top of that shift is why some clinicians describe menopause plus GLP-1 use as a kind of double hit. Women in this stage also start with less bone reserve than younger adults. It is worth remembering how common this overlap is: women ages 50 to 64 have the highest GLP-1 use of any group, and women 18 to 39 are the fastest-growing segment of users. If you are also weighing menopause treatment decisions, our piece on menopause hormone therapy and GLP-1s covers a related thread.

Muscle loss is part of the story too

Bone does not act alone. When you lose weight quickly, some of what you lose is lean muscle, and strong muscles help stimulate and maintain bone. Body-composition data from major trials show this clearly. In the SURMOUNT-1 imaging substudy, roughly a quarter of the total weight lost on tirzepatide came from lean mass, and in some semaglutide analyses that share has run higher. That does not mean the weight loss is not worthwhile. It means muscle is worth protecting on purpose rather than by accident.

What the research does and does not show

Here is the honest state of things. Very little research has looked at bone health specifically in people on GLP-1 medications, and what exists suggests a slight decrease in bone density similar to calorie restriction. Fracture data are genuinely mixed: some analyses have linked GLP-1 use to lower fracture or osteoporosis risk, while newer, longer studies in higher-risk adults have been less reassuring. A recurring finding is more encouraging: adding regular exercise, especially resistance training, appears to help preserve bone during weight loss. More research is still needed across different doses, ages, and sexes.

What women may want to keep an eye on

None of this is medical advice, and it is not a reason to fear treatment. It is a reason to be intentional. The habits researchers keep pointing to are the ordinary ones: adequate protein, resistance and weight-bearing exercise, and attention to calcium and vitamin D, plus bone-density monitoring for those at higher risk. Noticing patterns over time helps, and keeping a simple record of your doses, symptoms, and how you feel across your cycle can make those conversations with your clinician easier. If you want a starting framework, our guide on tracking peptides and GLP-1s alongside your cycle walks through it step by step.